Clinical features of COVID-19 mortality: development and validation of a clinical prediction model.


Journal

The Lancet. Digital health
ISSN: 2589-7500
Titre abrégé: Lancet Digit Health
Pays: England
ID NLM: 101751302

Informations de publication

Date de publication:
10 2020
Historique:
entrez: 28 9 2020
pubmed: 29 9 2020
medline: 29 9 2020
Statut: ppublish

Résumé

The COVID-19 pandemic has affected millions of individuals and caused hundreds of thousands of deaths worldwide. Predicting mortality among patients with COVID-19 who present with a spectrum of complications is very difficult, hindering the prognostication and management of the disease. We aimed to develop an accurate prediction model of COVID-19 mortality using unbiased computational methods, and identify the clinical features most predictive of this outcome. In this prediction model development and validation study, we applied machine learning techniques to clinical data from a large cohort of patients with COVID-19 treated at the Mount Sinai Health System in New York City, NY, USA, to predict mortality. We analysed patient-level data captured in the Mount Sinai Data Warehouse database for individuals with a confirmed diagnosis of COVID-19 who had a health system encounter between March 9 and April 6, 2020. For initial analyses, we used patient data from March 9 to April 5, and randomly assigned (80:20) the patients to the development dataset or test dataset 1 (retrospective). Patient data for those with encounters on April 6, 2020, were used in test dataset 2 (prospective). We designed prediction models based on clinical features and patient characteristics during health system encounters to predict mortality using the development dataset. We assessed the resultant models in terms of the area under the receiver operating characteristic curve (AUC) score in the test datasets. Using the development dataset (n=3841) and a systematic machine learning framework, we developed a COVID-19 mortality prediction model that showed high accuracy (AUC=0·91) when applied to test datasets of retrospective (n=961) and prospective (n=249) patients. This model was based on three clinical features: patient's age, minimum oxygen saturation over the course of their medical encounter, and type of patient encounter (inpatient An accurate and parsimonious COVID-19 mortality prediction model based on three features might have utility in clinical settings to guide the management and prognostication of patients affected by this disease. External validation of this prediction model in other populations is needed. National Institutes of Health.

Sections du résumé

Background
The COVID-19 pandemic has affected millions of individuals and caused hundreds of thousands of deaths worldwide. Predicting mortality among patients with COVID-19 who present with a spectrum of complications is very difficult, hindering the prognostication and management of the disease. We aimed to develop an accurate prediction model of COVID-19 mortality using unbiased computational methods, and identify the clinical features most predictive of this outcome.
Methods
In this prediction model development and validation study, we applied machine learning techniques to clinical data from a large cohort of patients with COVID-19 treated at the Mount Sinai Health System in New York City, NY, USA, to predict mortality. We analysed patient-level data captured in the Mount Sinai Data Warehouse database for individuals with a confirmed diagnosis of COVID-19 who had a health system encounter between March 9 and April 6, 2020. For initial analyses, we used patient data from March 9 to April 5, and randomly assigned (80:20) the patients to the development dataset or test dataset 1 (retrospective). Patient data for those with encounters on April 6, 2020, were used in test dataset 2 (prospective). We designed prediction models based on clinical features and patient characteristics during health system encounters to predict mortality using the development dataset. We assessed the resultant models in terms of the area under the receiver operating characteristic curve (AUC) score in the test datasets.
Findings
Using the development dataset (n=3841) and a systematic machine learning framework, we developed a COVID-19 mortality prediction model that showed high accuracy (AUC=0·91) when applied to test datasets of retrospective (n=961) and prospective (n=249) patients. This model was based on three clinical features: patient's age, minimum oxygen saturation over the course of their medical encounter, and type of patient encounter (inpatient
Interpretation
An accurate and parsimonious COVID-19 mortality prediction model based on three features might have utility in clinical settings to guide the management and prognostication of patients affected by this disease. External validation of this prediction model in other populations is needed.
Funding
National Institutes of Health.

Identifiants

pubmed: 32984797
doi: 10.1016/S2589-7500(20)30217-X
pii: S2589-7500(20)30217-X
pmc: PMC7508513
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Pagination

e516-e525

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI147028
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI136053
Pays : United States
Organisme : NIGMS NIH HHS
ID : P50 GM071558
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI118833
Pays : United States
Organisme : NIH HHS
ID : UG3 OD023337
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL147328
Pays : United States
Organisme : NHGRI NIH HHS
ID : U54 HG008098
Pays : United States

Commentaires et corrections

Type : UpdateOf
Type : CommentIn

Informations de copyright

© 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Chest. 2020 Aug;158(2):603-607
pubmed: 32339510
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Respir Res. 2020 Apr 15;21(1):83
pubmed: 32293449
EGEMS (Wash DC). 2013 Dec 17;1(3):1035
pubmed: 25848578
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Clin Infect Dis. 2020 Jul 28;71(15):833-840
pubmed: 32296824
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
J R Soc Interface. 2018 Apr;15(141):
pubmed: 29618526
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
N Engl J Med. 2020 May 7;382(19):1859
pubmed: 32220202
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
BMC Med. 2019 Dec 16;17(1):230
pubmed: 31842878
N Engl J Med. 2020 Jun 25;382(26):2582
pubmed: 32501665

Auteurs

Arjun S Yadaw (AS)

Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Yan-Chak Li (YC)

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Sonali Bose (S)

Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Ravi Iyengar (R)

Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Supinda Bunyavanich (S)

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Gaurav Pandey (G)

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH